Aeterna Zentaris Inc. (AEZS): Price and Financial Metrics

Aeterna Zentaris Inc. (AEZS): $3.72

-0.04 (-1.06%)

POWR Rating

Component Grades













Add AEZS to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where AEZS ranks best; there it ranks ahead of 87.98% of US stocks.
  • AEZS's strongest trending metric is Value; it's been moving up over the last 56 days.
  • AEZS's current lowest rank is in the Quality metric (where it is better than 5.8% of US stocks).

AEZS Stock Summary

  • The ratio of debt to operating expenses for AETERNA ZENTARIS INC is higher than it is for about just 4.63% of US stocks.
  • With a year-over-year growth in debt of -55.5%, AETERNA ZENTARIS INC's debt growth rate surpasses just 4.52% of about US stocks.
  • In terms of volatility of its share price, AEZS is more volatile than 96.5% of stocks we're observing.
  • Stocks that are quantitatively similar to AEZS, based on their financial statements, market capitalization, and price volatility, are MNDO, BGRY, MIRO, MTP, and IKT.
  • AEZS's SEC filings can be seen here. And to visit AETERNA ZENTARIS INC's official web site, go to

AEZS Valuation Summary

  • In comparison to the median Healthcare stock, AEZS's EV/EBIT ratio is 74.38% lower, now standing at 2.6.
  • AEZS's price/sales ratio has moved up 0.3 over the prior 243 months.

Below are key valuation metrics over time for AEZS.

Stock Date P/S P/B P/E EV/EBIT
AEZS 2023-01-30 2.8 0.4 -1.4 2.6
AEZS 2023-01-27 2.7 0.4 -1.3 2.7
AEZS 2023-01-26 2.7 0.4 -1.3 2.7
AEZS 2023-01-25 2.7 0.4 -1.4 2.7
AEZS 2023-01-24 2.7 0.4 -1.3 2.7
AEZS 2023-01-23 2.8 0.4 -1.4 2.6

AEZS Growth Metrics

    Its year over year net income to common stockholders growth rate is now at -30.25%.
  • Its 3 year net cashflow from operations growth rate is now at 30.24%.
  • Its 5 year revenue growth rate is now at 70.43%.
AEZS's revenue has moved up $5,043,000 over the prior 30 months.

The table below shows AEZS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 6.628 -12.669 -13.462
2022-06-30 5.37 -10.212 -11.74
2022-06-30 5.37 -10.212 -11.74
2022-03-31 6.191 -8.997 -9.563
2021-12-31 5.26 -8.581 -8.368
2021-12-31 5.26 -8.581 -8.368

AEZS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AEZS has a Quality Grade of F, ranking ahead of 3.18% of graded US stocks.
  • AEZS's asset turnover comes in at 0.128 -- ranking 241st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows AEZS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.128 0.366 4.492
2020-12-31 0.128 0.366 4.492
2019-12-31 0.024 0.229 2.567
2018-12-31 1.139 0.922 -4.563
2018-12-31 1.139 0.922 -4.563
2017-12-31 0.034 1.000 13.076

AEZS Stock Price Chart Interactive Chart >

Price chart for AEZS

AEZS Price/Volume Stats

Current price $3.72 52-week high $10.99
Prev. close $3.76 52-week low $2.89
Day low $3.72 Volume 19,698
Day high $3.90 Avg. volume 12,559
50-day MA $3.60 Dividend yield N/A
200-day MA $4.56 Market Cap 18.06M

Aeterna Zentaris Inc. (AEZS) Company Bio

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company was founded in 1991 and is based in Summerville, South Carolina.

AEZS Latest News Stream

Event/Time News Detail
Loading, please wait...

AEZS Latest Social Stream

Loading social stream, please wait...

View Full AEZS Social Stream

Latest AEZS News From Around the Web

Below are the latest news stories about AETERNA ZENTARIS INC that investors may wish to consider to help them evaluate AEZS as an investment opportunity.

Aeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19

Aeterna Zentaris Inc (NASDAQ: AEZS ) has decided to streamline development programs by discontinuing its early-stage vaccine programs . The company worked on evaluating administration routes, dosing, and immunization scheme and conducted in-vivo immunology experiments with candidate strains expressing various antigens in relevant mice models. To date, the company has not been able to select a clinical development candidate for a COVID-19 … Full story available on

Benzinga | January 17, 2023

Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones

Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across its development pipeline, advancing towards go/no-go decision milestones at each stage to establish prioritization and drive momentumStrategic decision to streamline development programs by discontinuing the Company’s early-stage vaccine programs provides Aeterna Zentaris with an expected extended cas

Yahoo | January 17, 2023

JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023.

Yahoo | January 11, 2023

Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 1

Yahoo | January 10, 2023

Aeterna Zentaris Reports Third Quarter 2022 Financial Results

– Company ended the quarter with $ 53.8 million in cash

GlobeNewswire | November 3, 2022

Read More 'AEZS' Stories Here

AEZS Price Returns

1-mo 15.53%
3-mo -7.23%
6-mo -25.15%
1-year -58.62%
3-year -85.69%
5-year -92.88%
YTD 16.98%
2022 -64.20%
2021 -16.50%
2020 -53.24%
2019 -69.05%
2018 24.58%

Continue Researching AEZS

Want to see what other sources are saying about Aeterna Zentaris Inc's financials and stock price? Try the links below:

Aeterna Zentaris Inc (AEZS) Stock Price | Nasdaq
Aeterna Zentaris Inc (AEZS) Stock Quote, History and News - Yahoo Finance
Aeterna Zentaris Inc (AEZS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7855 seconds.